Navigation Links
Synedgen Announces Issuance of Patent to Optimize Animal Health
Date:3/22/2013

Claremont CA (PRWEB) March 22, 2013

Synedgen Inc., a bio-pharmaceutical company developing novel therapies to prevent and treat infection and inflammation, announces that the United States Patent and Trademark Office (USPTO) has issued patent claims for the use of chitosan derivatives to treat or inhibit infections, and optimize animal health and weight gain to allow for the use of lower doses of antibacterial agents in animal feed. This issuance, U.S. Patent No. 8,399,635 Chitosan derivatives to treat animals or optimize animal health, continues the expansion of Synedgen’s patent portfolio.

The full patent covers methods of inhibiting the growth of or killing of bacteria, reducing bacterial load, preventing or delaying the onset of an infection, disease or disorder in an animal subject, and includes preparation, dosage and administration methods.

“The issuance of these claims enhances the strength of our growing IP portfolio,” stated Synedgen President Shenda Baker. “It describes the utility of our chitosan derivatives for infection control in food animals as well as the ability to synergize with traditional antibiotics used in their feed, dramatically reducing the amount of antibiotic used. These claims also complement the launch of Synoplex®, Synedgen’s veterinary wound rinse product designed to treat infected, chronic and non-infected wounds in elephants and rhinoceros.”

About Synedgen
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.

Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10558965.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
2. Piramal Imaging Announces the Acceptance for Review of [18F] florbetaben by the FDA and EMA for the Visual Detection of beta-amyloid in Alzheimers Disease
3. Probiotic Action Announces Probiotics Pending Listing on EU Foods
4. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
5. Neogen Corporation Announces 3rd Quarter Results Conference Call
6. Medifirst Solutions, Inc. Announces Further Update To Shareholders
7. Elsevier Announces the Launch of a New Journal: Wound Medicine
8. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
9. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
10. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
11. NineSigma Announces Winners in $25,000 Sustainable Packaging Challenge in Conjunction With Scientists Without Borders and Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... Mass. (PRWEB) , ... January 06, 2020 , ... ... for a Digital World at The Fletcher School at Tufts University, is pleased ... Sloan Foundation. The grant will be administered by Tufts University, and will help ...
(Date:12/31/2019)... ... December 31, 2019 , ... Vici ... development lab in Maryland. Emphasis will be in expanding capabilities in ... Vici Health Sciences will be well positioned to meet the growing demand for ...
(Date:12/27/2019)... ... December 27, 2019 , ... ... testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries is ... management . Following acquisition by CLJ Holdings in February, 2019, a comprehensive and ...
(Date:12/18/2019)... , ... December 17, 2019 , ... ... its 31st FDA clearance for reprocessing Electrophysiology (EP) devices since the company’s inception ... Stryker Sustainability Solutions and SterilMed (a Johnson & Johnson company) have received 2 ...
Breaking Biology Technology:
(Date:11/22/2019)... ... November 21, 2019 , ... ... Park Comprehensive Cancer Center have announced a major step forward with that therapy, ... have announced that the company, spun off from Roswell Park in 2012, has ...
(Date:11/19/2019)... ... ... The inaugural Cell & Gene Therapy Day takes place February 27, 2020 ... be chaired by Dr Aiman Shalabi, VP R&D, Cell and Gene Therapies for GSK, ... significant innovation in cell and gene therapies, and we are at a turning point ...
(Date:11/12/2019)... MEMPHIS, Tenn. (PRWEB) , ... November 12, 2019 ... ... in contract manufacturing of orthopedic medical devices, today announced the creation of a ... The reality in the Medical Device industry is that the regulatory element to ...
Breaking Biology News(10 mins):